Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 4;9(1):6.
doi: 10.1038/s41523-023-00509-2.

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

Maria Vittoria Dieci  1   2 , Giancarlo Bisagni  3 , Stefania Bartolini  4 , Antonio Frassoldati  5 , Roberto Vicini  6 , Sara Balduzzi  6 , Roberto D'amico  6   7 , Pierfranco Conte  8 , Valentina Guarneri  9   10
Affiliations

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

Maria Vittoria Dieci et al. NPJ Breast Cancer. .

Erratum in

Abstract

The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. We included in this analysis 784 patients with HR-positive/HER2-positive BC from the randomized ShortHER trial of adjuvant trastuzumab (1 year vs 9 weeks) + chemotherapy. At a median follow-up of 8.7 years, patients who received AI had a significantly better DFS vs patients who received TAM or TAM-AI: 8-yr DFS 86.4 vs 79.7%, log-rank P = 0.013 (HR 1.52, 95% CI 1.09-2.11). In multivariate analysis, the type of endocrine therapy maintained a significant association with DFS (HR 1.64, 95% CI 1.07-2.52, p = 0.025 for TAM/TAM-AI vs AI). Among premenopausal patients aged ≤45 years, the use of GnRHa was associated with longer DFS: 8-yr DFS rate 85.2 vs 62.6% (log-rank p = 0.019, HR 0.41, 95% CI 0.19-0.88). In this post-hoc analysis of the ShortHER trial adjuvant treatment with AI was independently associated with improved DFS. Subgroup analysis in premenopausal patients suggests benefits with ovarian suppression.Trial registration: NCI ClinicalTrials.gov number: NCT00629278.

PubMed Disclaimer

Conflict of interest statement

M.V.D. reports personal fees from Eli Lilly, Exact Sciences, Novartis, Pfizer, Seagen, Gilead, MSD, AstraZeneca, and Daiichi Sankyo outside the submitted work. A.F. reports personal fees from Roche, Novartis, Eli Lilly, AstraZeneca, Daiichi Sankyo, Seagen, and Gilead, outside the submitted work. P.C. reports personal fees from Novartis, Eli Lilly, AstraZeneca, Tesaro, Daiichi Sankyo, and Gilead, revealing Genomics, BMS, and Roche outside the submitted work. V.G. reports personal fees from Eli Lilly, Exact Sciences, Novartis, Pfizer, Gilead, MSD, Amgen, Sanofi, Merck Serono, and Eisai outside the submitted work. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. DFS Kaplan–Meier curves according to the type of adjuvant ET.
Comparison of AI vs TAM-AI vs TAM (a) and comparison of AI vs TAM/TAM-AI (b).
Fig. 2
Fig. 2. Annual hazard rates of DFS events for patients treated with AI or TAM.
The last timepoint considered is 108 months since the very low number of patients at risk in later years.
Fig. 3
Fig. 3
DFS Kaplan–Meier curves according to GnRHa use in premenopausal patients aged ≤45 years.
See this image and copyright information in PMC

References

    1. Cortés J, et al. HER2 and hormone receptor-positive breast cancer—blocking the right target. Nat. Rev. Clin. Oncol. 2011;8:307–311. doi: 10.1038/nrclinonc.2010.185. - DOI - PubMed
    1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. doi: 10.1038/nature11412. - DOI - PMC - PubMed
    1. Dieci MV, et al. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. Ann. Oncol. 2019;30:418–423. doi: 10.1093/annonc/mdz007. - DOI - PMC - PubMed
    1. Dieci MV, Guarneri V. Should triple-positive breast cancer be recognized as a distinct subtype? Expert Rev. Anticancer Ther. 2020;20:1011–1014. doi: 10.1080/14737140.2020.1829484. - DOI - PubMed
    1. Cameron D, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–1205. doi: 10.1016/S0140-6736(16)32616-2. - DOI - PMC - PubMed

Associated data